Cargando…

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

BACKGROUND: For many patients, current treatments do not adequately resolve heartburn in nonerosive reflux disease (NERD). OBJECTIVE: To compare vonoprazan and placebo with respect to the frequency and severity of heartburn in patients with NERD. METHODS: This Phase III, double-blind, placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinoshita, Yoshikazu, Sakurai, Yuuichi, Shiino, Madoka, Kudou, Kentaro, Nishimura, Akira, Miyagi, Takuya, Iwakiri, Katsuhiko, Umegaki, Eiji, Ashida, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238607/ https://www.ncbi.nlm.nih.gov/pubmed/28119763 http://dx.doi.org/10.1016/j.curtheres.2016.12.001

Ejemplares similares

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2019)

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
por: Iwakiri, Katsuhiko, et al.
Publicado: (2017)

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Antireflux surgery is equally beneficial in nonerosive and erosive gastroesophageal reflux disease
por: Park, Joong-Min, et al.
Publicado: (2018)

Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
por: Tabuchi, Maiko, et al.
Publicado: (2021)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
por: Sakurai, Yuuichi, et al.
Publicado: (2016)

The relationship between esophageal acidity and symptom frequency in symptomatic nonerosive gastroesophageal reflux disease
por: Gardner, Jerry D.
Publicado: (2022)

Nonerosive Reflux Disease (NERD) - An Update
por: Hershcovici, Tiberiu, et al.
Publicado: (2010)

Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan
por: Sakurai, Kouichi, et al.
Publicado: (2018)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Current Advances in the Diagnosis and Treatment of Nonerosive Reflux Disease
por: Chen, Chien-Lin, et al.
Publicado: (2013)

Progress on the Mechanism of Visceral Hypersensitivity in Nonerosive Reflux Disease
por: Xu, Cao, et al.
Publicado: (2022)

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease
por: Niikura, Ryota, et al.
Publicado: (2018)

Nonerosive gastroesophageal reflux disease and mild degree of esophagitis: Comparison of symptoms endoscopic, manometric and pH-metric patterns
por: Grande, Michele, et al.
Publicado: (2012)

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
por: Sugano, Kentaro
Publicado: (2018)

Juice Test for Identification of Nonerosive Reflux Disease in Heartburn Patients
por: Fernandes, Michel R, et al.
Publicado: (2018)

Role of Saliva in Esophageal Defense: Implications in Patients With Nonerosive Reflux Disease
por: Yandrapu, Harathi, et al.
Publicado: (2015)

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study
por: Kawai, Takashi, et al.
Publicado: (2018)

Correlation of Narrow Band Imaging Endoscopy and Histopathology in the Diagnosis of Nonerosive Reflux Disease
por: Arul, P, et al.
Publicado: (2015)

Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease
por: Gold, Benjamin D., et al.
Publicado: (2017)

Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021
por: Iwakiri, Katsuhiko, et al.
Publicado: (2022)

Characteristics of Symptom Presentation and Risk Factors in Patients with Erosive Esophagitis and Nonerosive Reflux Disease
por: Lee, Shou-Wu, et al.
Publicado: (2014)

Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease
por: Zheng, Ya-Mei, et al.
Publicado: (2021)

Multichannel impedance monitoring for distinguishing nonerosive reflux esophagitis with minor changes on endoscopy in children
por: Junko, Fujino, et al.
Publicado: (2021)

Oral soft tissue disorders are associated with gastroesophageal reflux disease: retrospective study
por: Watanabe, Masaaki, et al.
Publicado: (2017)

Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis
por: Kang, Hyun, et al.
Publicado: (2018)

Clinical significance of gastroesophageal reflux disease with minimal change: a multicenter prospective observational study
por: Manabe, Noriaki, et al.
Publicado: (2022)

Significantly Lower Saliva Secretion in Females With Gastroesophageal Reflux Disease and Healthy Subjects Than in Males
por: Momma, Eri, et al.
Publicado: (2023)

Herbal Medicine Hewei Jiangni Decoction Is Noninferior to Oral Omeprazole for the Treatment of Nonerosive Gastroesophageal Reflux Disease: A Randomized, Double-Blind, and Double-Dummy Controlled Trail
por: Li, Feng, et al.
Publicado: (2022)

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease
por: Miwa, Hiroto, et al.
Publicado: (2019)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
por: Mizokami, Yuji, et al.
Publicado: (2018)

Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptoms
por: Nakada, Koji, et al.
Publicado: (2017)

Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms
por: Wang, Dongke, et al.
Publicado: (2023)

Obesity and gastroesophageal reflux disease and gastroesophageal reflux symptoms in children
por: Malaty, Hoda M, et al.
Publicado: (2009)

Effects of Rikkunshito (TJ-43) on Esophageal Motor Function and Gastroesophageal Reflux
por: Morita, Terumi, et al.
Publicado: (2012)

Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteers
por: Ishimura, Norihisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ctrgfenruhv3sc491ujnn8e117